Skip to main content
. 2017 Aug 31;18(9):1875. doi: 10.3390/ijms18091875

Figure 3.

Figure 3

Efficacy of targeted therapies against a BRAF-V600E mutant melanoma PDOX. Relative tumor volume is the ratio of the tumor volume at any time point relative to the initial tumor volume. Only trametinib (TRA) could regress the tumor. Vemurafenib (VEM) was not very effective despite the fact that it targets the BRAF-V600E mutation in this tumor. ** p ≤ 0.0001. Error bars = SD [55].